FiercePharma |
Sanofi's eczema rollout Dupixent hits blockbuster launch trajectory as earnings beat
FiercePharma But so far, the numbers on Sanofi's new eczema med look even better, according to Bill Sibold, EVP at Sanofi Genzyme. “Prescriptions are trending ahead of other recent biologic launches in dermatology, including Cosentyx,” Sibold said during the … Sanofi raises outlook but key eczema drug disappoints investors France's Sanofi Raises Earnings Forecast, Pleased With Eczema Drug Uptake Sanofi raises outlook but key eczema drug disappoints investors |
